News coverage about Alliqua Biomedical (NASDAQ:ALQA) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alliqua Biomedical earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4961010654785 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Alliqua Biomedical (NASDAQ ALQA) traded up $0.03 on Monday, hitting $1.72. 28,800 shares of the stock were exchanged, compared to its average volume of 152,827. The stock has a market cap of $8.58, a price-to-earnings ratio of -0.17 and a beta of 1.10. Alliqua Biomedical has a 12-month low of $1.58 and a 12-month high of $8.50.
Separately, HC Wainwright set a $5.00 price target on shares of Alliqua Biomedical and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $8.20.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.